of call and and against year include initiatives this discussion some rest key announced. of a first the and After for our our I'll some CFO, progress we've that that, at XXXX. I'll how quarter to guidance this performance with updated objectives, drivers more on results good our point. we've Michael comments detailed the everyone. hand morning, you, for our financial I'll including quarter Turner, over the previously unfolding major made of we anticipate and begin Mick, Thank strategic partnerships the first morning
me quick current X, let dynamics, bifurcated, be the strong. remainder soft and that the to as a aligners clear that, Slide being business. more market our best we I'll describing characterized or specific begin quarter. the one can being start strongly and specifically, being with market being with the dental and with turn of dental With recap the In orthodontics negative,
as consumer inflation As focus the of market, has we have rent. as particularly has gas in as most and life last quarters, a been necessities know, discretionary many we've spending, strong forced consumers for food, reduced such by you impacted position few meeting demand to said this severely on
to pleased seems market that be yet has stabilizing, growth. While this to it we're to return
the to had inventory impact significantly period. the economic which market COVID on demand during desire levels, customers' Compounding reduce our has the been actual grown
expect pressure demand to come continue We year. the balance mid-year in and for this is then into our second and the through back half. guidance reflected supply moderate assumption This as in
in XXXX. deep anticipate inflation growth market be moderates, now ahead, as recession we provided returning would a Looking this can to avoided
story double-digit strong positive. the our revenue of very continues translated then the in This to Turning care again growth. orthopedic robust, business, be half health into to market QX which becomes
since models, human pioneer you on significantly musculoskeletal in beginning creation in XD that our As medical based many was expanding Systems orthopedic are applications of the early into of time, the a growing aware, customized with rapidly this and expertise. field, XXXXs
approvals accompanied company by for for a from titanic the and human medical spanning of undertaking that body to market. with models that not in disciplines required price the process world-class the any participate of wishes of requiring this applications the establishment was This the are practices, transition regulatory into with development quality success many technologies, entry company our years within only simple compelling
to Fast over additional And we've recognized the our plan our future. today, last orthopedic few business element is a focus skeletal indications craniomaxillofacial forward years, in applications. growth expanded key leader in orthopedic spinal many This in our include of a to and for system. strategic human expansion the we're the
We of so digital the that Learning to patient's platforms surgeon the planning to our and implants. require metal full increasing process medical these incorporates optimize advance surgical with finishing integration fully we with systems printing, continue saw of to then imaging and operations, some workflow patient's which indications and and hardware to new Machine polymer through orthopedic receipt material medical both from patient-specific now which printing that provide software and first, encompass AI and the the data, do the
request We number within bring life-changing and orthopedic daily. and initial surgical grows To-date, used the aid so, patients days do the instrumentation have in implants the to these customer this manufacturing can to guides, OR. the individual cutting surgeon of over process we XXX,XXX and to well while produce repairs
the and conveying do. of example nature is an fully we Often helpful what
a at If X, of patient an in left-hand of you'll actual the suffering you look tumor a their see cancerous from image in leg slide digital side number pelvic region.
of tumor of of of pelvis. have of limbs been would by removed the Amputation surrounding case, and in have bone part the patient which much cost type this would their this their one structure, Traditionally,
the to surgical Software, of were our tumor to the patient surgical removed. engineers use able the cutting Print that high-precision team be instrumentation DICOMJet print and carefully design Freeform guides allow the working needed our Through and with and
Optum manufactured with a to same operation, thereby Printing This using System. Printing DMP Expert XXX implant our Triflange bone remaining install patient-specific Then structure, avoiding in Metal the our in implant limb. titanium the amputation combination the XD reinforce custom Software complex was
the data, This days, medical first allowing treatment to done completed patient after receive diagnosis. was entire shortly needed so first in interaction the device the from process with patient the badly to they
the While technology economics now speed point remarkable, adoption. entire this workflow has the the improved of and large-scale orthopedic is itself to of
even and on push efficiency. ourselves to challenge to capability this progress, further cost with Even we continue
for platform moved which system, articulating are dual joint laser special human metal production many we titanium dramatically for material knee. in single the preferred the as to year, a replacement throughput, such on to this from applications repair and a that's in improves expanded we've example, recently use cobalt-chrome For a human materials, from and needed printing laser a body which focus
do but becoming the this printing, and through first XD We're customization of an opens and for active common aging which replacement, to the door is need degree greater much which economic a population. joint a
applications seeing greatly a types and application manufacturer. to are from be space on and as part a avoidance to connectors of of call markets. basis. can high and Solutions dedicated types would geometrically demand, benefit or lower very tooling which I also number continued volumes largely out driven electronics aviation attributed These additive regular the for electrical manufacturing, electronics complex that produced by group. of specifically and our hard military market, the injection Moving at strong automotive, Industrial We're for a leading molding their very capacity In
While a progressing and behind our some connectors announce first been the pleased efforts scenes world in for development sensors. with to were quarter, the connectors leader publicly has we time, TE Connectivity, in collaboration for our
The to right-hand solution use an Our stringent joint on flame regulatory XD UL network. to unique production the scale developing comprises within materials that software polymeric slide our illustrated global connectors for factory meet pass program the additive at first produce X manufacturing on solution standards known electrical and side for partner's requirements our UL of printing that modified services have modular global retardancy, our the a platform, Figure capability. been Sprint X focuses
the requirements meet newly to at we Instrumental a connectivity's produce to to engineered parallel specifically industrial in performance and that this photopolymer speeds success for the and precision developed has and an cost scale. been performance hardware
to is additive great a Connectivity manufacturing to build innovation has solutions. leaders of through potential us, their be we're partner. become This and significant with markets competitive accelerate customer advantage We believe we're in how the example to and industry for a partnering key TE honored
pleased investment address an XXXX progress some of making the As we're was on acquisitions. our to I'm recent year,
was first a Moving quarter, Group clinical the surgical to the of our early in polymers. Solutions medical-grade PEEK polymeric this process printer. European for XD shared similar regulators at Salzburg specifically milestone material for executed a printing with from the cranial This of received a the the Healthcare high-performance implantation plate printer US Hospital underway Last Austria's for is medical-grade a University when by X. team printed manufactured of major developed in and the slide using They achievement approval procedure we Kumovis precision FDA.
installed precisely match Trummer after the relief a team cranial point the Kumovis patient-specific this Mr. with at the of A physiological Using him. we're thrilled and anatomical that customized months the procedure to to needs. hospital, implant printer and is Trummer was related printed for profile inside performed, Mr. and brought -- surgical few the and the a care
software, time a staff and that needs. surgeons comprehensive for manufacturing talented believe the of use the through provides specific the technologies orthopedic technology Hospital and potential hardware of a to outcomes enhancing the brought in materials first Salzburg a indebted We deeply this within unique together setting hospital the real-life setting. address digital to we are success hospital for We demonstration at University our point-of-care
these is patients will that benefits our we company one on bring focus Our key believe significant years and ahead. integrated point-of-care around implementation the world to technologies in the of a for priority
on after his of weeks for a very is and picture where Here's Mr. apparent track surgery, recovery several Trummer the all.
and of Oqton,, is automation the system area comprehensive dental next acquired manufacturing date, the we and regarding manufacturing announced recent slide operating labs have in months this which to Oqton's reduce cloud-based adoption market. in you its first production environments several to the software worldwide efficiencies I in The digital on news unique XX system costs. Oqton's update first X. AI-enabled and adopted our the now availability. deployment turning accelerates recently dental division, system Now manufacturing the hundred operating in to improve of on XXXX. Oqton update To want
negative are that of their the are quickly to to is first sites. rapidly for an platform has lifetime Oqton migrating rates five churn their XX% to as year by not of Production creation in value the renewing With implementation positive value demonstrated only using acquisition Dental expanding demonstrates cost XX% feedback from the licenses, adoption. throughout gains meaning at the ratio efficiency they're number of of each initial and been negative operational licenses exceeded XX% Lab of customer now the the their ranging over overwhelmingly customers customer that operations, software, to manage
Slide on efforts. to I'd moving updates exciting recent Now some to provide most like of X. our R&D some
focus for called the development a use by develop of our in tissue in the announced Another strategically vascularized last important company start-up and medicine, printing, to year we unique and organ-on-a-chip technology regenerative Bio, pharmaceutical manufacture and leveraging investment h-VIOS industry. discovery was formation that's expertise Systemic owned of have drug area wholly
and specific to organ then Systemic Bio disease will jointly to pharmaceutical industry partner to functions directly with h-VIOS that and biotech am in application and drug directly pharmaceutical tailored for chips partners company with announce that a chip major today to those chips contract develop h-VIOS we've companies signed market pharmaceutical are of engaged technology. our first I discovery. very happy major our
we While program, the tumor bioprinted we drug do company name, used to will and permission to this have in establish in be for a yet oncology. discovery development disclose not efforts model vascularized
this accelerate therapies initial lines Given technology. in initial new the to through efforts early our to the about anticancer the to test This multiyear a the variety using the of the cycle h-VIOS drug development of therapies development use widespread tumor patient-specific extremely h-VIOS view our through of adoption of of therapies. our response new potential excited time approach reducing development for industry, for the tumor of technology chip a will contract models. patient's validation be will these collaboration as a We're and our seek
X. Turning Slide then to
key consistent company to our offer healthcare industrial investment R&D additive before, that stated and ongoing mission provide a new and are regarding markets. returns initiatives our our product that we only attractive and we application-focused to to we've are additions end manufacturing As solutions portfolio point high-growth pursuing is high-value, programs believe with
you in SLS acquisition enhance the we offering were Wematter. our selective planned As saw our our with laser to centering week, of announcement very excited last
line enterprise smaller for affordable of production potential solutions gravity SLS their accessible printers, customers manufacturing turnkey, whose broader population Wematter of essential brings limited. enabling to make an a SLS essential an With environments, space plus closed-loop is
over research and medical of enables types portfolio address to wide academic industrial, their material range of for addition, them SLS a applications markets. device In XX
recycling use a and emphasizes for on integrated ease and sustainability new unique Wematter and Importantly, focus environmental its handling installation a standard with of customer powder system.
our While continued important such smaller, our to printing of development strategic in having but play emerging with applications business needs, we've viewed across program a having our expansion internal a to role customer as bolt-on technology robust is customer-specific most meet their Wematter into acquisitions unique new units. two
close July. the in transaction to Wematter early expect We
last internal garner the release. our our development laser a continues the dual SLA and announcement pleased year remains that excitement to first share for printer, track Shifting on Dual, late of efforts, synchronous revolutionary I'm world's XXX SLA to to summer
three mechanical the through leader dramatically a As trailblazing performance. select we'll and be system, with reminder, throughput This surface cost with times resolution, productivity confirmed of accuracy as our industrial improving customers, dual the extensive SLA parts and platforms, size, speed the twice of printing testing industry the unmatched competing finish and beta efficiency. speed, delivering in print delivers
and health goods, When and for X. in it the We system a durable such that power transportation, believe of care platform, services, technology unlocks to seamless mainstay years industries the manufacturing on sports, Factory leverage many Okta aerospace become true manufacturing follow. with as the consumer this motor will integration
introducing provide an change if discipline there's it's on of to newest and In note. previous addition I initiatives, to some announcements, to good a growth update our our believe particularly directional
Using speed, The much lines, standard a industrial technology, XXXX, and customers which increased capability, to several these the that material high-temperature called use product partner and of material, Along a of for build longtime to Roadrunner. with this is input we was precision. area extrusion development collaboration Roadrunner we aims enhanced larger a February including product Jabil with benefits capable markets, and Jabil supplying. customer Corporation, offer in of a would film intent announced
technology, we to which pellet the material underway, including cost. a moving studying a got alternatives, for potential extrusion program lower this offered much as However, continue
company we small dug such Colorado developed called in As that have printing platform. we discovered Titan a further, Robotics a
Systems sure that across market platforms system. the and machine platform we of rapidly customer a systems. short to XD from In Titan to Roadrunner family industrial order, acquire the gaining quicker, outset elected attributes looking full path integrated a the we operating many printing the net the Today, result in were in acceptance of and at is significant The Titan into for markets. and is for production, several was
CumoVIS, earlier, developments upon to platforms extrusion talented Since and be acquisition Titan are acquiring both extrusion CumoVIS that to in being move with from a now and tuned for group we offing. subsequent technology through medical high-performance the investments future into grade novel of this which, developed our they're our and very gleaned build may our of technology of Stay reinforced we've in as the both engineers, as mentioned internal Titan continued integrated broader has expanded market. on ourselves this Through aerospace and platform, polymers. continue Roadrunner well area the for a son I the
partnership matrix which The XXXX, we'd focused regenerative second announced the on is on breast in we in update use that to tissue the soft you June of for like bioprinted initiative reconstruction.
both exploratory initial suited soft our tissue for reconstruction promising, breast sciences program applications. the partners' better which our we were in other While believe, efforts material progressed, results laboratories of developed as materials, alternative independently we're the and
by printing in detailed these year. This and own our to program shown We remain have tissue our this about As the this of in earlier to have program. year, completed February we this continue pursue in number the using of We this made to-date decided this release soft subsequently effort that ourselves tissue printing from increasing animal promise studies excited technology. human the of we applications that applications large the as human announced. efforts we continued we've great in effort materials emerge has unique vascularized and in such, rapidly
well with platform, strategic along select regarding our that markets. we're printing industrial the customers key quite phase growth Polar, DP first healthcare and launch units high-speed the with of will in beta moving acquisition And finally, rotary
designed first feedback units of initial from fall. in units again expect you to of late We follow for in and the be these this We'll specifically polymer high-speed launch. high-mix gain customer These high-volume we installed summer components. once printing the trial to update as more are
XX. slide to moving Now
Before on to and for update I'd beyond. you to turning our the XXXX outlook like over call Michael,
statement Let of philosophy. me very make a clear operating our
to exciting demonstrate that deliver to needed in investment can rapidly As we sufficient and order to ongoing a levels both support are important requirements we meet that it's believe our expanding applications. customer the leader profitability growth industry, in
As and our product to under restructuring by a announced such, engineering the earlier that highest profit our manufacturing our initiative our long-term and operations better portfolio now bring improve platforms year, metals software profile on focusing our is this the to organization, which we value European three XXXX often, aligning for consolidated market. platforms, streamlining
to functions night, approximately with We step And efforts structure, well last environment. in by all it's We're manage announced headcount prudently the front. we expanded progressing the with feel very macroeconomic this X% broader restructuring reduce now our associated on company. to we've necessary our as the of uncertainties cost across
in us cost the importantly, year productivity more most our And are progresses. previous allowing now investments to harvest efficiencies as
have As to with EBITDA later, free Michael for you guidance million adjusted flow. in our outlook in profit will deliver to more change gross detail our margin or cash non-GAAP $X revenue, no for XXXX and increased we
I'd that material closing, that's is arisen and our not businesses and question historic additional choosing address of to company us the industrial regarding some we're like medicine, to revenue follow our from generating analysts, core regenerative for which In in make the a investments who today. healthcare
particularly, why, Very specifically, are investments. these choosing we we're these to challenging in being asked times, make
year other possible invest Bio of let human million related our tissue initiatives there Systemic to within non-organ to full and XXXX about be guidance, Including me plan million magnitude a our as First, medicine investment. $XX as between development. regenerative $XX the clear in is our and
from this this greater be support performance were our To these for is if external state simple. our we EBITDA would obvious, committed partner, we're addition much reason to effort, In this, making year. development significant human The efforts Therapeutics. that we're the not very investments to United receiving our also organ
that field core to unprecedented and in It's to positioned more an we're the of a incredibly to are in strong uniquely we opportunity for lives with who series We our drive highly exciting change and position the drive an impact have to and medicine with tens unique them inherent society. and importantly, in of can on unlock of businesses future from life-changing in have our people's significant potential fortunate benefit fund strategic be change a a of profit-generating And portfolio. company the to technology. this opportunity thousands sheet of investments balance the
The including peoples lives importantly, employees benefit for be will exceptional. we all stakeholders our the impact shareholders, our will and that
As at time stated United I'll self remind frame, event. life CEO, goal to of partner, last that sponsored Therapeutics our you the CNM summer's Rothblatt, Martine our of
But within a a organ to goal five trials. closer making years, this a clinical will human in year printed reality. have Today, we're
more thriving. leadership needed to that ensure to Until announcements expect efforts the can then, making our human each are our the We're retain market core we position. You key related pharmaceutical and businesses future. in progress in our
And our on and our let discussion for with detail Michael? Michael me outlook. to financial that, more turn over the performance
